Alnylam Pharmaceuticals/ALNY

13:30
20:25
03:15
10:10
17:00
1D1W1MYTD1YMAX

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Ticker

ALNY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

2,100

ALNY Metrics

BasicAdvanced
$31B
Market cap
-
P/E ratio
-$2.65
EPS
0.41
Beta
-
Dividend rate
$31B
0.41
3.174
2.859
-1,184.124
-1,224.187
-1.38%
-3.05%
138.80%
15.5
-143.36
-143.36
242.94
75.20%
-69.51%
51.96%
-29.48%

What the Analysts think about ALNY

Analyst Ratings

Majority rating from 29 analysts.
Buy

ALNY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-13.33% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$494M
12.42%
Net income
-$66M
-52.18%
Profit margin
-13.33%
-57.45%

ALNY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.04%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.21
$1.15
-$1.10
-$0.52
-
Expected
-$1.37
-$1.34
-$1.32
-$1.18
-$1.11
Surprise
61.47%
-186.09%
-16.84%
-56.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals (ALNY) has a market cap of $31B as of July 03, 2024.

What is the P/E ratio for Alnylam Pharmaceuticals stock?

The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of July 03, 2024.

Does Alnylam Pharmaceuticals stock pay dividends?

No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Alnylam Pharmaceuticals dividend payment date?

Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.

What is the beta indicator for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Alnylam Pharmaceuticals stock

Buy or sell Alnylam Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing